Rexhepaj, Elton <br/><br/>
Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.  [electronic resource] 

 -  BMC cancer  Nov 2010 
 - 639 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Validation Study 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-10-639  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Algorithms<br/>Biomarkers, Tumor--analysis<br/>Breast Neoplasms--chemistry<br/>Cell Nucleus--chemistry<br/>Chi-Square Distribution<br/>Cytoplasm--chemistry<br/>Decision Trees<br/>Estrogen Receptor Modulators--therapeutic use<br/>Female<br/>Humans<br/>Image Interpretation, Computer-Assisted<br/>Immunohistochemistry<br/>Inhibitor of Apoptosis Proteins<br/>Kaplan-Meier Estimate<br/>Ki-67 Antigen--analysis<br/>Microtubule-Associated Proteins--analysis<br/>Middle Aged<br/>Pattern Recognition, Automated<br/>Predictive Value of Tests<br/>Proportional Hazards Models<br/>Receptor, ErbB-2--analysis<br/>Receptors, Estrogen--analysis<br/>Receptors, Progesterone--analysis<br/>Reproducibility of Results<br/>Risk Assessment<br/>Risk Factors<br/>Survivin<br/>Sweden<br/>Tamoxifen--therapeutic use<br/>Time Factors<br/>Tissue Array Analysis<br/>Treatment Outcome